Over the past decade, several multikinase inhibitors have shown considerable effectiveness against metastatic radioiodine-refractory thyroid cancers in early stage clinical trials. On the basis of some remarkable results in a phase III clinical trial, lenvatinib now joins sorafenib as another multikinase inhibitor approved by the FDA for this disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic advances in anaplastic thyroid cancer: a current perspective
Molecular Cancer Open Access 23 October 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Matsui, J. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 14, 5459–5465 (2008).
Matsui, J. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 122, 664–671 (2008).
Wilhelm, S. M. et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015).
Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014).
Tuttle, R. M. et al. NCCN clinical practice in oncology for thyroid carcinoma. Version 2.2014. National Comprehensive Cancer Network [online] (2014).
Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205–2218 (2013).
Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605–622 (2014).
Sherman, E. J. et al. A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. J. Clin. Oncol. 29 (Suppl.), a5566 (2011).
Knauf, J. A. & Fagin, J. A. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr. Opin. Cell Biol. 21, 296–303 (2009).
Acknowledgements
We are grateful to Alan L. Ho for helpful comments on the manuscript. This work was supported, in part, by NIH grants CA50706, CA72597, P50-CA72012 and P30-CA008748.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dunn, L., Fagin, J. Lenvatinib and radioiodine-refractory thyroid cancers. Nat Rev Endocrinol 11, 325–327 (2015). https://doi.org/10.1038/nrendo.2015.53
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.53
This article is cited by
-
Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway
Molecular Biology Reports (2019)
-
Therapeutic advances in anaplastic thyroid cancer: a current perspective
Molecular Cancer (2018)
